Yue Chen

8.1k total citations · 1 hit paper
340 papers, 4.9k citations indexed

About

Yue Chen is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Yue Chen has authored 340 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Oncology, 86 papers in Radiology, Nuclear Medicine and Imaging and 85 papers in Surgery. Recurrent topics in Yue Chen's work include Peptidase Inhibition and Analysis (94 papers), Radiopharmaceutical Chemistry and Applications (59 papers) and Protease and Inhibitor Mechanisms (57 papers). Yue Chen is often cited by papers focused on Peptidase Inhibition and Analysis (94 papers), Radiopharmaceutical Chemistry and Applications (59 papers) and Protease and Inhibitor Mechanisms (57 papers). Yue Chen collaborates with scholars based in China, United States and South Sudan. Yue Chen's co-authors include Robert Dales, Mei‐Hsiang Lin, Zhongyi Cheng, Liang Cai, Huipan Liu, Shaozhi Fu, Zhanwen Huang, Yue Feng, Jeong Soo Yang and Shuzhen Zheng and has published in prestigious journals such as Nature Communications, Blood and Gastroenterology.

In The Last Decade

Yue Chen

306 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The First Identification of Lysine Malonylation Substrates and Its Regulatory Enzyme

2011 597 citations Yue Chen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yue Chen China	35	1.5k	1.1k	1.1k	692	671	340	4.9k
Corrado Rubini Italy	40	1.7k 1.1×	2.4k 2.2×	1.0k 1.0×	997 1.4×	660 1.0×	261	6.2k
Paolo Pedrazzoli Italy	38	1.9k 1.2×	960 0.9×	723 0.7×	348 0.5×	747 1.1×	288	5.5k
Tetsuya Yamamoto Japan	41	1.0k 0.7×	1.6k 1.4×	1.2k 1.1×	757 1.1×	1.0k 1.6×	329	6.4k
Bin Cheng China	42	1.1k 0.7×	1.9k 1.7×	615 0.6×	968 1.4×	631 0.9×	221	5.8k
Shankargouda Patil India	32	436 0.3×	1.6k 1.4×	374 0.3×	568 0.8×	330 0.5×	388	5.5k
Angelo Carpi Italy	43	1.2k 0.8×	1.2k 1.0×	1.3k 1.2×	490 0.7×	499 0.7×	233	6.1k
Marilene B. Wang United States	35	996 0.6×	1.5k 1.3×	1.9k 1.7×	479 0.7×	867 1.3×	185	5.8k
Bo Li China	36	989 0.6×	1.9k 1.6×	890 0.8×	888 1.3×	501 0.7×	238	4.3k
Miguel Ángel González‐Moles Spain	43	1.1k 0.7×	1.1k 1.0×	982 0.9×	362 0.5×	419 0.6×	170	5.9k
Ashok Gupta India	35	3.3k 2.2×	1.0k 0.9×	1.6k 1.5×	512 0.7×	1.2k 1.9×	252	6.3k

Countries citing papers authored by Yue Chen

Since Specialization

Citations

This map shows the geographic impact of Yue Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yue Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yue Chen more than expected).

Fields of papers citing papers by Yue Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yue Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yue Chen. The network helps show where Yue Chen may publish in the future.

Co-authorship network of co-authors of Yue Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Yue Chen. A scholar is included among the top collaborators of Yue Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yue Chen. Yue Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Yuanyuan, Jinming Yu, Jing Wang, et al.. (2025). Synthesis and evaluation of 177Lu-labeled anti-EGFR Fab antibody for lung cancer. Journal of Radioanalytical and Nuclear Chemistry. 334(3). 2139–2149.

Chen, Yue, Kai Zhao, Cong Wang, et al.. (2025). The glymphatic system in neurodegenerative diseases and brain tumors: mechanistic insights, biomarker advances, and therapeutic opportunities. Acta Neuropathologica Communications. 14(1). 19–19.

Chen, Guang, S. H. Zhou, Yue Chen, et al.. (2025). Traditional Chinese medicine and natural products in management of hepatocellular carcinoma: Biological mechanisms and therapeutic potential. Pharmacological Research. 215. 107733–107733. 1 indexed citations

Liu, Yang, Haiyang Li, Nan Liu, et al.. (2025). Development and Application of Radioactive Ligands Targeting Fibroblasts with Albumin-Binding Sites. Molecular Cancer Therapeutics. 24(8). 1186–1196. 2 indexed citations

Li, Haiyang, Yang Liu, Ping Cai, et al.. (2025). Development and Evaluation of Novel ⁶⁸Ga/¹⁷⁷Lu-Labeled PSMA Inhibitors with Enhanced Pharmacokinetics and Tumor Imaging for Prostate Cancer. Molecular Pharmaceutics. 22(3). 1584–1597. 1 indexed citations

Li, Taotao, Yue Chen, Yu Zhou, et al.. (2024). Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial. Oral Oncology. 159. 107087–107087.

Wang, Wei‐Ming, et al.. (2024). Mulberroside A attenuates cigarette smoke-induced atherosclerosis in ApoE−/− mice via the Sirt1-HIF-1α axis. Cellular Signalling. 124. 111400–111400. 2 indexed citations

Wu, Xin, et al.. (2024). Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level HER-2 expression: a case report. Frontiers in Oncology. 14. 1339806–1339806. 4 indexed citations

Liu, Mengna, Xi Chen, Haoyuan Ding, et al.. (2024). Comparison of [18F]FDG and [68 Ga]pentixafor PET/CT in Nasopharyngeal Carcinoma. Molecular Imaging and Biology. 26(4). 658–667. 3 indexed citations

10.

Wang, W., et al.. (2024). 177Lu-FAP-2286 Therapy in a Patient With Metastatic Rhabdoid Meningioma. Clinical Nuclear Medicine. 49(9). 879–881. 5 indexed citations

11.

Zhang, Huihui, et al.. (2023). Imageological/Structural Study regarding the Improved Pharmacokinetics by 68Ga-Labeled PEGylated PSMA Multimer in Prostate Cancer. Pharmaceuticals. 16(4). 589–589. 6 indexed citations

12.

Su, Dan, Hongyu Yang, Qiu Chen, & Yue Chen. (2023). Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis. Frontiers in Oncology. 13. 1141648–1141648. 4 indexed citations

13.

Liu, Nan, Yue Feng, Yang Liu, et al.. (2023). High Affinity and FAP-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake for FAP Inhibitors. Journal of Medicinal Chemistry. 66(13). 8614–8627. 14 indexed citations

14.

Liu, Shufen, et al.. (2023). Prenatal whole exome sequencing identified two rare compound heterozygous variants in EVC2 causing Ellis‐van Creveld syndrome. Molecular Genetics & Genomic Medicine. 11(10). e2242–e2242. 1 indexed citations

15.

Tang, Shan, Yan Zhang, Yunfei Li, et al.. (2023). Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer. Frontiers in Immunology. 14. 1034416–1034416.

16.

Xu, Tingting, et al.. (2022). Application of ⁶⁸Ga-citrate PET/CT for differentiating periprosthetic joint infection from aseptic loosening after joint replacement surgery. Bone and Joint Research. 11(6). 398–408. 10 indexed citations

17.

Xiong, Kang, Qian Wen, Jia Luo, et al.. (2020). Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy. International Journal of Pharmaceutics. 589. 119875–119875. 77 indexed citations

18.

Wu, Chen‐Fei, Jia‐Wei Lv, Li Lin, et al.. (2020). Development and validation of a web‐based calculator to predict individualized conditional risk of site‐specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases. Cancer Communications. 41(1). 37–50. 12 indexed citations

19.

Lv, Jia‐Wei, Yu‐Pei Chen, Guan‐Qun Zhou, et al.. (2019). Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nature Communications. 10(1). 3941–3941. 111 indexed citations

20.

Wang, Jing, Liangang Zhuo, Wei Liao, et al.. (2017). Assessing the Biocidal Activity and Investigating the Mechanism of Oligo-p-phenylene-ethynylenes. ACS Applied Materials & Interfaces. 9(9). 7964–7971. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact